AI assistant
Sending…
Keros Therapeutics, Inc. — Director's Dealing 2024
Feb 16, 2024
32602_dirs_2024-02-15_c132b94d-b949-4eb6-95b7-f6b9f81de488.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2024-02-13
Reporting Person: Cooper Simon Peter (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-13 | Employee Stock Option (right to buy) | $56.18 | A | 40000 | Acquired | 2034-02-12 | Common Stock (40000) | Direct |
Footnotes
F1: 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
More from Keros Therapeutics, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 3
Regulatory Filings
2026
Jun 1
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 22
Proxy Solicitation & Information Statement
2026
Apr 22
Investor Presentation
2026
Mar 4
Annual Report
2026
Mar 4
Regulatory Filings
2026
Mar 4
Director's Dealing
2026
Feb 26